These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 16874487)

  • 1. The cytotoxic T cell response to peptide analogs of the HLA-A*0201-restricted MUC1 signal sequence epitope, M1.2.
    Mitchell MS; Lund TA; Sewell AK; Marincola FM; Paul E; Schroder K; Wilson DB; Kan-Mitchell J
    Cancer Immunol Immunother; 2007 Mar; 56(3):287-301. PubMed ID: 16874487
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of three non-VNTR MUC1-derived HLA-A*0201-restricted T-cell epitopes that induce protective anti-tumor immunity in HLA-A2/K(b)-transgenic mice.
    Heukamp LC; van der Burg SH; Drijfhout JW; Melief CJ; Taylor-Papadimitriou J; Offringa R
    Int J Cancer; 2001 Feb; 91(3):385-92. PubMed ID: 11169964
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of HLA-A2-restricted T-cell epitopes derived from the MUC1 tumor antigen for broadly applicable vaccine therapies.
    Brossart P; Heinrich KS; Stuhler G; Behnke L; Reichardt VL; Stevanovic S; Muhm A; Rammensee HG; Kanz L; Brugger W
    Blood; 1999 Jun; 93(12):4309-17. PubMed ID: 10361129
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recognition of breast cancer cells by CD8+ cytotoxic T-cell clones specific for NY-BR-1.
    Wang W; Epler J; Salazar LG; Riddell SR
    Cancer Res; 2006 Jul; 66(13):6826-33. PubMed ID: 16818660
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel breast-tumor-associated MUC1-derived peptides: characterization in Db-/- x beta2 microglobulin (beta2m) null mice transgenic for a chimeric HLA-A2.1/Db-beta2 microglobulin single chain.
    Carmon L; El-Shami KM; Paz A; Pascolo S; Tzehoval E; Tirosh B; Koren R; Feldman M; Fridkin M; Lemonnier FA; Eisenbach L
    Int J Cancer; 2000 Feb; 85(3):391-7. PubMed ID: 10652432
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The HIV-1 HLA-A2-SLYNTVATL is a help-independent CTL epitope.
    Kan-Mitchell J; Bisikirska B; Wong-Staal F; Schaubert KL; Bajcz M; Bereta M
    J Immunol; 2004 May; 172(9):5249-61. PubMed ID: 15100263
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Definition of an immunogenic region within the ovarian tumor antigen stratum corneum chymotryptic enzyme.
    Bondurant KL; Crew MD; Santin AD; O'Brien TJ; Cannon MJ
    Clin Cancer Res; 2005 May; 11(9):3446-54. PubMed ID: 15867247
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of a human CD8+ T lymphocyte neo-epitope created by a ras codon 12 mutation which is restricted by the HLA-A2 allele.
    Bergmann-Leitner ES; Kantor JA; Shupert WL; Schlom J; Abrams SI
    Cell Immunol; 1998 Aug; 187(2):103-16. PubMed ID: 9732698
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A human cytotoxic T-lymphocyte epitope and its agonist epitope from the nonvariable number of tandem repeat sequence of MUC-1.
    Tsang KY; Palena C; Gulley J; Arlen P; Schlom J
    Clin Cancer Res; 2004 Mar; 10(6):2139-49. PubMed ID: 15041735
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel epitope evoking CD138 antigen-specific cytotoxic T lymphocytes targeting multiple myeloma and other plasma cell disorders.
    Bae J; Tai YT; Anderson KC; Munshi NC
    Br J Haematol; 2011 Nov; 155(3):349-61. PubMed ID: 21902685
    [TBL] [Abstract][Full Text] [Related]  

  • 11. DCs pulsed with novel HLA-A2-restricted CTL epitopes against hepatitis C virus induced a broadly reactive anti-HCV-specific T lymphocyte response.
    Guo Z; Zhang H; Rao H; Jiang D; Cong X; Feng B; Wang J; Wei L; Chen H
    PLoS One; 2012; 7(6):e38390. PubMed ID: 22701633
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An altered HLA-A0201-restricted MUC1 epitope that could induce more efficient anti-tumor effects against gastric cancer.
    Yu H; Ye C; Li J; Pan C; Lin W; Chen H; Zhou Z; Ye Y
    Exp Cell Res; 2020 May; 390(1):111953. PubMed ID: 32156601
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of an HLA-A*0201-restrictive CTL epitope from MUC4 for applicable vaccine therapy.
    Wu J; Wei J; Meng K; Chen J; Gao W; Zhang J; Xu Z; Miao Y
    Immunopharmacol Immunotoxicol; 2009; 31(3):468-76. PubMed ID: 19555216
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A newly identified MAGE-3-derived epitope recognized by HLA-A24-restricted cytotoxic T lymphocytes.
    Oiso M; Eura M; Katsura F; Takiguchi M; Sobao Y; Masuyama K; Nakashima M; Itoh K; Ishikawa T
    Int J Cancer; 1999 May; 81(3):387-94. PubMed ID: 10209953
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A single amino acid substitution in HLA-A2 can alter the selection of the cytotoxic T lymphocyte repertoire that responds to influenza virus matrix peptide 55-73.
    Shimojo N; Cowan EP; Engelhard VH; Maloy WL; Coligan JE; Biddison WE
    J Immunol; 1989 Jul; 143(2):558-64. PubMed ID: 2472444
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recognition of PSA-derived peptide antigens by T cells from prostate cancer patients without any prior stimulation.
    Chakraborty NG; Stevens RL; Mehrotra S; Laska E; Taxel P; Sporn JR; Schauer P; Albertsen PC
    Cancer Immunol Immunother; 2003 Aug; 52(8):497-505. PubMed ID: 12783216
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An altered peptide ligand for naïve cytotoxic T lymphocyte epitope of TRP-2(180-188) enhanced immunogenicity.
    Tang Y; Lin Z; Ni B; Wei J; Han J; Wang H; Wu Y
    Cancer Immunol Immunother; 2007 Mar; 56(3):319-29. PubMed ID: 16906394
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Peptides derived from human insulin-like growth factor-II mRNA binding protein 3 can induce human leukocyte antigen-A2-restricted cytotoxic T lymphocytes reactive to cancer cells.
    Tomita Y; Harao M; Senju S; Imai K; Hirata S; Irie A; Inoue M; Hayashida Y; Yoshimoto K; Shiraishi K; Mori T; Nomori H; Kohrogi H; Nishimura Y
    Cancer Sci; 2011 Jan; 102(1):71-8. PubMed ID: 21087352
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Induction of human cytotoxic T lymphocytes that preferentially recognise tumour cells bearing a conformational p53 mutant.
    McArdle SE; Rees RC; Mulcahy KA; Saba J; McIntyre CA; Murray AK
    Cancer Immunol Immunother; 2000 Oct; 49(8):417-25. PubMed ID: 11043848
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Her-2/ neu altered peptide ligand-induced CTL responses: implications for peptides with increased HLA affinity and T-cell-receptor interaction.
    Dionne SO; Myers CE; Smith MH; Lake DF
    Cancer Immunol Immunother; 2004 Apr; 53(4):307-14. PubMed ID: 14605764
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.